Heptocellular Carcinoma (HCC) Resource Page



Hepatocellular Carcinoma (HCC) is the most common cancer of the liver and the sixth most common cancer worldwide. Imaging plays a crucial role in HCC monitoring and diagnosis, as well as in clinical trials, where imaging can be used to plan therapies and evaluate response to treatment. However, the asymmetrical nature of HCC lesions and coexistence of chronic liver disease or cirrhosis in many patients makes accurate evaluation of HCC tumor response a unique challenge. Additionally, various imaging modalities offer their own benefits and disadvantages in assessing HCC tumor response.

We at Keosys have numerous resources available exploring the complexities and emerging innovations in the field of imaging in the treatment of HCC. Use these resources to discover trends and predictions from oncology and radiology experts, delve into best-practice examples from the field, and to gain deeper insights into the current and future state of imaging’s role in monitoring HCC. 

HCC Resource Library

  • eBook: Hepatocellular Carcinoma and Imaging in Clinical Trials
    Find out more about the use of imaging to evaluate HCC in this 17-page eBook. Learn how imaging is used to monitor liver disease, detection of HCC, and tumor response. Gain an understanding of the read criteria used to evaluate tumor response in HCC in clinical trials. Examine the benefits and limitations of imaging modalities to assess HCC and explore emerging opportunities using Selective Internal Radiation Therapy (SIRT). Download the eBook.

  • Infographic: Modified RECIST for HCC
    mRECIST was developed in 2010 to adapt RECIST v1.1 to the particularities of Hepatocellular Carcinoma (HCC). This infographic provides an overview of all the key points to keep in mind regarding mRECIST. View and download the infographic.

  • Interview: An Interventional Radiologist Talks About Radioembolization in the Treatment of HCC Today
    Yan Rolland, head of the diagnosis and interventional radiology department at Centre Eugène Marquis, in Rennes, France, has been working to improve the treatment of hepatocellular carcinoma (HCC) for more than 30 years. Dr. Rolland recently spoke with Keosys about his career and the state of radioembolization today. Read excerpts from our conversation.
  • Interview: A Radiology Professor Talks About mRECIST, Reading Images in Clinical Trials, and More
    Maxime Ronot, Professor at the Université de Paris, and Radiologist in the Department of Medical Imaging at the Beaujon University Hospital in Clichy, France, has been working in Hepatocellular Carcinoma (HCC) since 2008. We recently spoke with Prof. Ronot about the intricacies and challenges of using mRECIST to assess treatment response in HCC and his work as a Professor of Radiology. Learn more about our conversation.

We hope clinical trial professionals find our HCC resources informative and helpful. For the latest news and insights about medical imaging, clinical trials, and Keosys, please subscribe to our monthly newsletter.



Immunology eBook

More Posts

New call-to-action